




RealRate

HEALTH SERVICES 2016

Viridian Therapeutics Inc DE
Rank 32 of 78



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Viridian Therapeutics Inc DE are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Viridian Therapeutics Inc DE compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 331% points. The greatest weakness of Viridian Therapeutics Inc DE is the variable Net Income, reducing the Economic Capital Ratio by 113% points.

The company's Economic Capital Ratio, given in the ranking table, is 232%, being 95% points above the market average of 137%.

Input Variable	Value in 1000 USD
Assets, Current	11,734
Assets, Non-Current	0
Cost of Goods and Services Sold	2,472
Depreciation, Depletion, Amortization	0
General and Administrative Expense	7,692
Goodwill Impairment Loss	0
Intangible Assets	0
Labor Expense	0
Liabilities, Current	2,468
Long Term Liabilities	0
Operating Costs and Expenses	0
Other Assets	15
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	0
Other Revenues	2,538
Property Plant and Equipment	1,153
Research And Development Expense	1,002
Selling and Marketing Expense	2,559

Output Variable	Value in 1000 USD
Assets	12,902
Liabilities	2,468
Expenses	13,725
Revenues	2,538
Stockholders Equity	10,434
Net Income	-11,187
Comprehensive Net Income	-11,187
Economic Capital Ratio	232%